Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. Further, the company has collaboration with Asembia to enhance provider and patient experience through nationwide digital services and hub support for harrow's branded eyecare products. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee. more
Time Frame | HROW | Sector | S&P500 |
---|---|---|---|
1-Week Return | -3.61% | -2.12% | -3% |
1-Month Return | -19.37% | -3.42% | -0.73% |
3-Month Return | -23.99% | -11.13% | 2.87% |
6-Month Return | 71.7% | -5.74% | 7.17% |
1-Year Return | 241.86% | 3.97% | 25.31% |
3-Year Return | 302.59% | 1.05% | 28.38% |
5-Year Return | 377.93% | 34.37% | 81.89% |
10-Year Return | 327.75% | 97.88% | 183.27% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 51.16M | 48.87M | 72.48M | 88.59M | 130.19M | [{"date":"2019-12-31","value":39.3,"profit":true},{"date":"2020-12-31","value":37.54,"profit":true},{"date":"2021-12-31","value":55.67,"profit":true},{"date":"2022-12-31","value":68.05,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 16.75M | 14.46M | 18.21M | 25.38M | 39.64M | [{"date":"2019-12-31","value":42.25,"profit":true},{"date":"2020-12-31","value":36.49,"profit":true},{"date":"2021-12-31","value":45.95,"profit":true},{"date":"2022-12-31","value":64.03,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 34.42M | 34.41M | 54.26M | 63.21M | 90.55M | [{"date":"2019-12-31","value":38.01,"profit":true},{"date":"2020-12-31","value":38,"profit":true},{"date":"2021-12-31","value":59.92,"profit":true},{"date":"2022-12-31","value":69.81,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 67.26% | 70.41% | 74.87% | 71.35% | 69.55% | [{"date":"2019-12-31","value":89.84,"profit":true},{"date":"2020-12-31","value":94.04,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":95.3,"profit":true},{"date":"2023-12-31","value":92.9,"profit":true}] |
Operating Expenses | 35.18M | 33.66M | 52.40M | 61.29M | 90.12M | [{"date":"2019-12-31","value":39.03,"profit":true},{"date":"2020-12-31","value":37.35,"profit":true},{"date":"2021-12-31","value":58.14,"profit":true},{"date":"2022-12-31","value":68.01,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (503.00K) | (1.63M) | (284.00K) | (1.75M) | 431.00K | [{"date":"2019-12-31","value":-116.71,"profit":false},{"date":"2020-12-31","value":-378.65,"profit":false},{"date":"2021-12-31","value":-65.89,"profit":false},{"date":"2022-12-31","value":-405.1,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Total Non-Operating Income/Expense | (2.12M) | (6.04M) | (24.92M) | (23.17M) | (45.70M) | [{"date":"2019-12-31","value":-212200000,"profit":false},{"date":"2020-12-31","value":-603600000,"profit":false},{"date":"2021-12-31","value":-2492400000,"profit":false},{"date":"2022-12-31","value":-2317400000,"profit":false},{"date":"2023-12-31","value":-4569600000,"profit":false}] |
Pre-Tax Income | (125.00K) | (3.42M) | (17.87M) | (14.01M) | (23.94M) | [{"date":"2019-12-31","value":-12500000,"profit":false},{"date":"2020-12-31","value":-341500000,"profit":false},{"date":"2021-12-31","value":-1787400000,"profit":false},{"date":"2022-12-31","value":-1401100000,"profit":false},{"date":"2023-12-31","value":-2394100000,"profit":false}] |
Income Taxes | 2.47M | 4.00K | 133.00K | 75.00K | 470.00K | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":0.16,"profit":true},{"date":"2021-12-31","value":5.39,"profit":true},{"date":"2022-12-31","value":3.04,"profit":true},{"date":"2023-12-31","value":19.05,"profit":true}] |
Income After Taxes | (2.59M) | (3.42M) | (18.01M) | (14.09M) | (24.41M) | [{"date":"2019-12-31","value":-259200000,"profit":false},{"date":"2020-12-31","value":-341900000,"profit":false},{"date":"2021-12-31","value":-1800700000,"profit":false},{"date":"2022-12-31","value":-1408600000,"profit":false},{"date":"2023-12-31","value":-2441100000,"profit":false}] |
Income From Continuous Operations | (125.00K) | (3.42M) | (18.01M) | (14.09M) | (24.41M) | [{"date":"2019-12-31","value":-12500000,"profit":false},{"date":"2020-12-31","value":-341900000,"profit":false},{"date":"2021-12-31","value":-1800700000,"profit":false},{"date":"2022-12-31","value":-1408600000,"profit":false},{"date":"2023-12-31","value":-2441100000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (2.59M) | (3.42M) | (18.01M) | (14.09M) | (24.41M) | [{"date":"2019-12-31","value":-259200000,"profit":false},{"date":"2020-12-31","value":-341900000,"profit":false},{"date":"2021-12-31","value":-1800700000,"profit":false},{"date":"2022-12-31","value":-1408600000,"profit":false},{"date":"2023-12-31","value":-2441100000,"profit":false}] |
EPS (Diluted) | 0.15 | (0.43) | (0.66) | (0.40) | (0.74) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-286.67,"profit":false},{"date":"2021-12-31","value":-440,"profit":false},{"date":"2022-12-31","value":-266.67,"profit":false},{"date":"2023-12-31","value":-493.33,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
HROW | |
---|---|
Cash Ratio | 0.76 |
Current Ratio | 1.55 |
Quick Ratio | 1.44 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
HROW | |
---|---|
ROA (LTM) | -1.68% |
ROE (LTM) | -50.23% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
HROW | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.84 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.16 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
HROW | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 7.25 |
P/B | 20.94 |
Price/FCF | 505 |
EV/R | 7.91 |
EV/Ebitda | 1255.60 |
Harrow Health Inc (HROW) share price today is $34.22
Yes, Indians can buy shares of Harrow Health Inc (HROW) on Vested. To buy Harrow Health Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in HROW stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Harrow Health Inc (HROW) via the Vested app. You can start investing in Harrow Health Inc (HROW) with a minimum investment of $1.
You can invest in shares of Harrow Health Inc (HROW) via Vested in three simple steps:
The 52-week high price of Harrow Health Inc (HROW) is $59.23. The 52-week low price of Harrow Health Inc (HROW) is $9.13.
The price-to-earnings (P/E) ratio of Harrow Health Inc (HROW) is
The price-to-book (P/B) ratio of Harrow Health Inc (HROW) is 20.94
The dividend yield of Harrow Health Inc (HROW) is 0.00%
The market capitalization of Harrow Health Inc (HROW) is $1.23B
The stock symbol (or ticker) of Harrow Health Inc is HROW